It is a single dose. It will be tested on 60,000 people in the US and other countries, including Argentina.
Johnson & Johnson The final stage of a massive study began Wednesday to try to show whether a vaccine from single dose against COVID-19 can protect against coronavirus.
It will be one of the further studies of vaccines in the world against the coronavirus so far, as it will test the vaccine in 60,000 volunteers in the United States, Mexico, Argentina, Brazil, Chile, Colombia, Peru and South Africa.
Other vaccines in the United States – including those made by Moderna Inc. and Pfizer Inc., and others in several countries – are already in the final stages of testing. There is high hope that by the end of the year there will be success with at least one of the candidates that are being tested in the United States, maybe before.
US health officials insist that the global search for a vaccine is not taking shortcuts risky.
“We want to do everything we can without sacrificing safety or efficacy. We are not going to do that, to make sure we end up with vaccines that will save lives” Dr. Francis Collins, director of the US National Institutes of Health (NIH), told reporters.
Still, many vaccine specialists wonder if the Food and Drug Administration (FDA) will stick to that goal under the intense pressure of the administration of President Donald Trump, who is seeking reelection in the November elections.
Trump has consistently come up with a faster schedule for a new vaccine than experts say is appropriate.
On Wednesday, Trump tweeted a news report on the Johnson & Johnson study, saying the FDA “must act quickly.”
Meanwhile, the trial of another experimental vaccine, made by AstraZeneca, remains detained temporarily in the United States while authorities examine security issues, despite the fact that studies with her have already resumed in other countries.
Days ago, Vice President Mike Pence urged state governors to “do their part to build public confidence that it will be a safe and effective vaccine.”